Sunstone

Results: 48



#Item
1VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo

VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo

Add to Reading List

Source URL: sunstone.eu

Language: English - Date: 2016-07-12 04:22:18
2PRESS RELEASE F2G Ltd announces the appointment of Ralf Schmid to the position of Chief Financial Officer MANCHESTER, UK – 11 JulyF2G Ltd, the UK-based antifungal drug discovery and development company, today a

PRESS RELEASE F2G Ltd announces the appointment of Ralf Schmid to the position of Chief Financial Officer MANCHESTER, UK – 11 JulyF2G Ltd, the UK-based antifungal drug discovery and development company, today a

Add to Reading List

Source URL: sunstone.eu

Language: English - Date: 2016-07-18 05:53:44
3

PDF Document

Add to Reading List

Source URL: sunstone.eu

Language: Danish - Date: 2015-11-27 06:54:44
    4    Introducing  the  NVPI      –  Nordic  Venture  Performance  Index  2014   Nordic  Venture  Capital  has  created    

        Introducing  the  NVPI      –  Nordic  Venture  Performance  Index  2014   Nordic  Venture  Capital  has  created    

    Add to Reading List

    Source URL: sunstone.eu

    Language: English - Date: 2015-11-27 06:54:51
      5Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology  Partnership aims to advance development of novel immune checkpoint

      Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology  Partnership aims to advance development of novel immune checkpoint

      Add to Reading List

      Source URL: sunstone.eu

      Language: English - Date: 2016-01-04 04:51:17
        6Anergis Closes CHF 5 Million Financing Round Extension to Conduct Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT  Arrangements started for largest field trial ever conducted with an ultra-fast t

        Anergis Closes CHF 5 Million Financing Round Extension to Conduct Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT  Arrangements started for largest field trial ever conducted with an ultra-fast t

        Add to Reading List

        Source URL: sunstone.eu

        Language: English - Date: 2016-04-04 04:09:41
          7Sunstone West 2011 Preliminary Program                           (Every effort will be made to keep to this schedule but session times, topics, and speakers may change). Fri

          Sunstone West 2011 Preliminary Program                           (Every effort will be made to keep to this schedule but session times, topics, and speakers may change). Fri

          Add to Reading List

          Source URL: www.sunstonemagazine.com

          Language: English - Date: 2012-05-08 07:47:01
            8

            PDF Document

            Add to Reading List

            Source URL: sunstone.eu

            - Date: 2014-12-11 04:47:52
              9Jurag June 13th, 2007 Jurag Separation A/S establish licensing agreement with Chr. Hansen A/S The agreement with Chr. Hansen, a leading manufacturer of food ingredients, demonstrates commercial viability of Jurag Separat

              Jurag June 13th, 2007 Jurag Separation A/S establish licensing agreement with Chr. Hansen A/S The agreement with Chr. Hansen, a leading manufacturer of food ingredients, demonstrates commercial viability of Jurag Separat

              Add to Reading List

              Source URL: sunstone.eu

              Language: English - Date: 2014-10-27 08:42:57
                10The Company Established in 2007 and headquartered in Copenhagen, Sunstone is a leading European Venture Capital fund. The fund consists of one investment team in Technology and one in Life Science. Sunstone Life Science

                The Company Established in 2007 and headquartered in Copenhagen, Sunstone is a leading European Venture Capital fund. The fund consists of one investment team in Technology and one in Life Science. Sunstone Life Science

                Add to Reading List

                Source URL: sunstone.eu

                Language: English - Date: 2015-03-19 07:54:05